Provided by Tiger Trade Technology Pte. Ltd.

KINTOR PHARMA-B

2.750
-0.250-8.33%
Volume:4.30M
Turnover:11.99M
Market Cap:1.37B
PE:-7.63
High:2.950
Open:2.900
Low:2.720
Close:3.000
52wk High:4.700
52wk Low:1.050
Shares:499.00M
HK Float Shares:499.00M
Volume Ratio:0.36
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.361
ROE:-54.99%
ROA:-17.21%
PB:5.58
PE(LYR):-7.63
PS:109.81

Loading ...

From 22% Plunge to 1.5% Uptick: Has China's Pharma Distribution Leader Stabilized After Management Overhaul?

Deep News
·
Yesterday

Wellington Management Increases Stake in GENFLEET-B by 3.82 Million Shares at HK$25.5 Each

Stock News
·
Yesterday

Kintor Pharma Moves Board Meeting to 30 March 2026

Bulletin Express
·
Yesterday

Kintor Pharmaceutical postpones board meeting to approve annual results

Reuters
·
Yesterday

KINTOR PHARMA-B Shares Extend Decline, Dropping Over 9% Amid Ongoing "Whitening Ingredient" Dispute

Stock News
·
Yesterday

GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting

Stock News
·
Mar 20

Three Chinese Firms Including Tiandi Science & Technology Have IPO Applications Accepted by Regulator

Stock News
·
Mar 20

Haina Pharmaceutical's Third IPO Attempt: Cash Flow Strain and Persistent Profit Decline Challenge Generic Drug CXO Narrative

Deep News
·
Mar 20

Wellington Management Group LLP Increases Stake in GENFLEET-B by 2.524 Million Shares

Stock News
·
Mar 19

CHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%

Stock News
·
Mar 19

BRIEF-Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint

Reuters
·
Mar 18

Kintor Pharma-B (09939) Reports KX-826 Phase III Trial Achieves Primary Endpoint in Male AGA Treatment

Bulletin Express
·
Mar 18

Kintor Pharma-B Achieves Primary Endpoint in Phase III Trial of KX-826 for Male Hair Loss

Stock News
·
Mar 18

Kintor says China Phase III trial of KX-826 1.0% for male AGA met its primary endpoint

Reuters
·
Mar 18

Kintor Pharmaceutical Ltd - Pharma's Kx-826 Phase Iii Trial in China Reaches Primary Endpoint

THOMSON REUTERS
·
Mar 18

Official Approval Granted: Two Vocational Colleges in Shandong Upgrade to University Status, Binzhou Medical College Renamed Shandong Medical University

Deep News
·
Mar 18

Kintor Pharma-B Shares Surge Over 5% in Morning Session on Strategic Skincare Partnership

Stock News
·
Mar 18

KINTOR PHARMA-B (09939) Forms Exclusive Alliance with Chicmax (02145) to Fast-Track Commercialisation of Whitening Ingredient KT-939

Bulletin Express
·
Mar 17

Shanghai Chicmax Cosmetic signs strategic cooperation agreement with Suzhou Kintor for KT-939 commercialization

Reuters
·
Mar 17

Baiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing

Stock News
·
Mar 16